| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
Many studies have suggested that type 2 diabetes is associated with an increased risk of several neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s diseases (PD). The ketogenic diet has been used for almost 100 years to treat refractory childhood epilepsy. It has also been studied as a potential therapy for other neurologic diseases, such as PD and AD. Hydroxycarboxylic acid receptor 2 (HCA2), also known as GPR109A, is a G protein-coupled anti-inflammatory receptor. It is present in macrophages, neutrophils and microglia. Beta-hydroxy butyrate (BHB) was identified as the physiological ligand of HCA2.
BHB suppressed LPS-induced expression of IL-6 and IL-1 beta in mouse microglia BV-2 cells. The phosphorylation of Erk1/2 was inhibited by the treatment of BHB, but the activation of the NF-kappa B pathway was not significantly influenced.
|
